Key Point {#S0001}
=========

When drug loading efficiency was 15%, the most efficient drug encapsulation was 60.9%, the dose of MTX was reduced in Fe~3~O~4~\@MTX MNPs for thermochemotherapy compared with the single chemotherapy group. Therefore, we could improve the therapeutic effect while reducing the chemotherapeutic drugs.In the study, we found that combined thermochemotherapy can promote apoptosis and shrink tumors. In addition, we explored the possible pathways by detecting the expression of apoptosis-related genes Caspase-3, Bax and Bcl-2.

Introduction {#S0002}
============

Primary central nervous system lymphoma (PCNSL) is an extranodal malignant non-Hodgkin lymphomas (NHL) that arise exclusively in the CNS, including the brain, leptomeninges, spinal cord and eyes.[@CIT0001]--[@CIT0003] Diffuse large B-cell lymphoma (DLBCL) is the most common histological subtype (\>90%).[@CIT0004] It is a rare neoplasm with a median age of 66 years at diagnosis, accounting for 2--3% of all NHL cases but in increasing incidence particularly for elderly patients.[@CIT0005],[@CIT0006] So far, the use of high-dose intravenous (IV) methotrexate (MTX) as the backbone regimens, with or without whole-brain radiotherapy and other chemotherapeutics, resulted in significantly improved efficacy, achieving response rates (RR) as high as 70--90%, and median overall survival (OS) of 40--70 months.[@CIT0007],[@CIT0008] However, it is now widely recognized that the need for high doses of chemotherapy to achieve valid drug concentrations in cerebral tissues and/or radiotherapy results in a high incidence of delayed neurologic toxicity, occurring in as many as 90% of patients who are older than 60 years.[@CIT0009],[@CIT0010] Despite recent therapeutic progress and an apparent improvement in survival figures, outcomes for patients with primary CNS lymphoma remain poor with 20--30% survival at 5 years, clinical research in this field is focused predominantly on the identification of new active agents and combinations to increase efficacy and tolerability of induction chemotherapy.[@CIT0011]

In recent times, nanotechnology is extensively offering new approaches to drug delivery, disease diagnose and therapy, especially in cancer research. Functionalization of nanoparticles with cytotoxic drugs has been proven a promising cancer therapeutic method to selectively target tumor cells and reduce systemic toxicity of drugs.[@CIT0012],[@CIT0013] One promising cancer therapeutic method is magnetic hyperthermia; tumor cells can effectively be killed by heating to hyperthermic temperatures (42--45°C) during the exposure to an alternating magnetic field (AMF).[@CIT0013]--[@CIT0018] It involves raising the local temperature of the local malignant tissues which results in an induced cell death without damaging the surrounding healthy tissues, therefore making the cancer cells more sensitive to the effects of certain anti-cancer drugs and minimizing the collateral damage caused by other well-established therapies.[@CIT0015],[@CIT0019] Among the nanocarriers that used for drug delivery and cancer therapy, iron oxide nanoparticles (Fe~3~O~4~) are relatively easy to synthesise, biocompatible, nontoxic, chemically stable and can be superparamagnetic, which have attracted considerable attention for tumor targeting thermochemotherapy.[@CIT0019]--[@CIT0021]

Herein, iron oxide magnetic nanoparticles (IONPs) Fe~3~O~4~ as a carrier can move to the tumor location with an external magnetic field after loading the drug, and produce a combined thermochemotherapy effect under magnetic resonance imaging (MRI) monitoring.[@CIT0018],[@CIT0022]--[@CIT0024] In our study，the antitumor activity of water-dispersible Pluronic F-127/OA-coated Fe~3~O~4~\@MTX nanoparticle formulation was developed in order to lower the use of chemotherapy drug MTX and reduce toxic effects, at the same time achieving better inhibition of PCNSL.

Materials and Methods {#S0003}
=====================

Materials {#S0003-S2001}
---------

The transmission electron microscope was from Hitachi (Japan). The nanoparticle tracking analysis (NTA) and Zeta potentiometer were from Malvern (United Kingdom). UV-VIS-NIR spectrophotometer UV-3600 was from Shimadzu (Japan). Vibrating sample magnetometry (VSM) PPMS-9 (Quantum Design, USA); StepOnePlus™ Real-Time PCR System (Applied Biosystems); BD FACSCantotm II Flow Cytometry (BD Biosciences, USA). A SPG-06A high-frequency induction heater was purchased from ShuangPing (Shenzhen, China). RPMI-1640 medium and DMEM medium (Gibco, Thermo Fisher Scientific), heat-inactivated fetal bovine serum (Gibco, Life Technologies), penicillin-streptomycin (Gibco, Life Technologies). Other reagents included ferric chloride (FeCl~3~•6H~2~O), ferrous sulfate (FeSO~4~•7H~2~O) and ammonia water (NH~3~•H~2~O), etc. which were purchased from Shanghai First Reagent Factory (China), Methotrexate (MTX) (donated by Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, Jiangsu，China). Cell Counting Kit-8，CCK-8 (KeyGEN BioTECH，China), RNA pure Tissue & Cell Kit (DNase I) (Cwbiotech, China). Quantitative Real-time-PCR related reagents were purchased from Vazyme (Vazyme Biotech Co., Ltd, China), Caspase-3 primer, Bax primer, Bcl-2 primer and GAPDH primer were purchased from Invitrogen. Goat anti-Rabbit IgG (KeyGEN BioTECH, China), GAPDH (KeyGEN BioTECH, China), Caspase-3 antibody, Bax antibody and Bcl-2 antibody were purchased from Cell Signaling Technology (USA). All reagents were analytical grade.

Cells and Animals {#S0003-S2002}
-----------------

3T3 cells were purchased from Shanghai Institute of Cell Biology (Shanghai, China). DLBCL cell line (OCI-LY18 cells) were from DSMZ (Biomart，China). KM mice (male and female, SPF grade), age-matched (4--6 weeks of age) and weight-matched (20--25 g) were purchased from Cavens Lab Animal Company (Changzhou, China，License number: SCXK (Jiangsu) 2016-0010); BALB/c-Nude mice (male and female, SPF grade), age-matched (4--6 weeks of age) and weight-matched (18--22 g) were purchased from Animal Core Facility of Nanjing Medical University. The ethical review has passed by Nanjing Medical University (Approval No. IACUC-1810012), and the relevant experimental personnel are certified. All animals received humane care in compliance with the "Principles of Laboratory Animal Care" formulated by the National Society for Medical Research and the "Guide for the Care and Use of Laboratory Animals" prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No 86--23, revised 1996). Animal modeling was assessed by MRI, tumor volume was calculated and compared among each group of treatment.

Preparation of Fe~3~O~4~ MNPS {#S0003-S2003}
-----------------------------

Based on previous research[@CIT0025]，28g of FeCl~3~•6H~2~O, 20g of FeSO~4~•7H~2~O were dissolved in deoxygenated ddH~2~O，kept stirring with nitrogen until the temperature of the system exceeded 70°C. 40ml NH~3~•H~2~O and 5ml OA were added in sequence. After washing the OA-coated MNPS, Pluronic F-127 was added，followed by magnetic stirring overnight. The larger particles were removed by centrifugation at low speed, and then centrifuged at high speed to discard the excess Pluronic F-127. Finally, stable Pluronic F-127/OA-coated MNPs were obtained and stored at 4°C for further use.

Encapsulation and Cumulative Release of MTX {#S0003-S2004}
-------------------------------------------

We set series of concentrations of MTX and Pluronic F-127/OA-coated MNPs (MTX:Fe = 5, 10, 15, 20, 25, 30, 35, 40; %W/W) disperse in phosphate-buffered solution (PBS). The mixture was shaken and incubated at 25°C for 72 hrs to allow MTX to be entrapped into OA layer. Free MTX was removed by magnetic separation. The supernatant was discarded and the complexes were resuspended and sonicated in PBS buffer to form a homogeneous solution and stored at 4°C. The amount of non-entrapped MTX in aqueous phase was determined using UV-VIS-NIR spectrophotometer (370nm; Shimadzu, Japan). The amount of MTX entrapped within the nanoparticles was calculated by the difference between the total amount used to prepare the nanoparticles and drug encapsulation efficiency was calculated as follows: (amount of loaded drug in mg)/(amount of added drug in mg) × 100%; Drug loading was calculated as follows: (amount of loaded drug in mg)/(amount of MNPs in mg) ×100%.

Furthermore, the drug release study of Fe~3~O~4~\@MTX MNPs was carried out in pH 7.4 PBS. The released MTX concentrations from the nano-carriers were determined by UV-VIS-NIR spectrophotometer; supernatants from Fe~3~O~4~\@MTX complexes were collected after magnetic separation within three days (after 2 hrs, 4 hrs, 6 hrs, 12 hrs, 24 hrs, 48 hrs, 72 hrs) at 25°C and 42°C, respectively.

Characterization of Fe~3~O~4~ MNPs and Fe~3~O~4~\@MTX MNPs {#S0003-S2005}
----------------------------------------------------------

The Fe~3~O~4~ MNPs and Fe~3~O~4~\@MTX MNPs samples were spread onto 400 mesh copper grids. The size and shape of the Fe~3~O~4~ nanoparticles were determined by TEM (Hitachi, Japan). The NTA (Malvern, UK) was used to detect size distribution, and the magnetic properties of the nanoparticles were analyzed by vibrating sample magnetometry (Quantum Design, USA) at room temperature. Zeta potential was measured using Malvern Instruments (Malvern, UK).

Increasing Temperature Tests {#S0003-S2006}
----------------------------

Magnetothermal effects of MNPs were tested in aqueous suspensions (0.5, 1.0, 1.5 mg Fe/mL). The solution was placed in a flat-bottomed test tube on an SPG-06A high-frequency induction heater (f = 230 kHz; I = 30 A; Shenzhen, China) for 60 mins. The temperature was recorded at 5-mins intervals.

Biocompatibility {#S0003-S2007}
----------------

### Cell Culture {#S0003-S2007-S3001}

3T3 cells were maintained in DMEM medium (Gibco, Thermo Fisher Scientific), mixed with 10% fetal bovine serum (Gibco, Life Technologies) and 1% penicillin-streptomycin (Gibco, Life Technologies) in a standard 5% CO~2~ and 37°C incubator. The cells were passaged every 2--3 days and harvested on exponential growth stage.

### CCK-8 Cytotoxicity Test {#S0003-S2007-S3002}

CCK-8 assay was used to evaluate cell toxicity. 3T3 cells were seeded in 96-well plates (8000 cells per well) for 24 hrs in DMEM medium. Then they were divided into eleven groups (four wells per group) and incubated with various concentrations of Fe~3~O~4~ MNPs solution and Fe~3~O~4~\@MTX MNPs solution (Fe concentration：20，40，60，80，100，200，300，400，500 μg/mL), control group (DMEM medium containing 10% fetal bovine serum) and blank group (DMEM medium containing 10% fetal bovine serum without cells) for 24 hrs. Inverted microscopy (Olympus, Japan) was used to observe general morphological changes of the 3T3 cells, and then the CCK-8 assay was performed and the optical density (OD) values were measured at 450 nm. The cell viability was calculated as follows: (OD of experimental group--OD of blank group)/(OD of negative control group--OD of blank group)

### Micronucleus Assay of Fe~3~O~4~ MNPs {#S0003-S2007-S3003}

The KM mice were randomly divided into six groups, with five females and five males in each group. The animals were then treated with four concentrations of Fe~3~O~4~ MNPs (5.00, 3.75, 2.50 and 1.25 g/kg), 0.9% saline (as negative group) and Cyclophosphamide (CTX) 40 mg/kg (as positive group), respectively. All experimental mice were injected intraperitoneally twice, with a 24-hrs interval, and then sacrificed 6 hrs after the second administration. The thighbone marrows were extracted for smears, fixed 15 mins with methanol, and then washed slides after stained with Giemsa for 15 mins. At least 1000 polychromatic erythrocytes (PEC) were counted for each mouse, and the rate of formation of PEC containing micronucleus (MN) was calculated. SPSS was used to analyze statistic difference between each group.

### Acute Toxicity Testing of Fe~3~O~4~\@MTX MNPs {#S0003-S2007-S3004}

The KM mice were randomly assigned into eight groups, with five females and five males in each group. After dissolved in 0.9% saline, Fe~3~O~4~\@MTX MNPs were injected intraperitoneally into the mice at dosages of 1.77, 2.51, 3.54, 5.00, 7.06, 9.98, 14.09, and 19.89 g/kg. The general behavior of the mice was observed continuously for 2 hrs immediately after injection and then intermittently observed for a period of 24 hrs. All mice were further observed for up to 14 days after injection, and general physical states, including eating, rest and movement were monitored. Any toxic reaction and death were recorded. Median lethal dose (LD~50~) was evaluated by SPSS. The animals were euthanized after all of the experiment.

In vitro Evaluation of the Efficacy of Fe~3~O~4~\@MTX MNPs on OCI-LY8 PCNSL Cells {#S0003-S2008}
---------------------------------------------------------------------------------

### Cell Culture and Perls Stain {#S0003-S2008-S3001}

An OCI-LY8 DLBCL cell line was cultured in RPMI1640 medium (Gibco, Thermo Fisher Scientific) supplemented with 10% heat-inactivated fetal bovine serum (Gibco, Life Technologies), 1% penicillin-streptomycin (Gibco, Life Technologies) and incubated at 37°C with humidified air containing 5% CO~2~.

OCI-LY8 cells were seeded into a culture dish (1×10^6^ cells) with fresh medium and incubated (37°C, 5% CO~2~) overnight. The growth medium was then discarded and replaced with fresh medium containing Fe~3~O~4~\@MTX MNPs (Fe concentration: 1.0 mg/mL). The cells were incubated (37°C, 5% CO~2~) for an additional 1 hr; after that, the medium was discarded and cells washed. After fixation by methanol, cells were stained by Perls and observed with an inverted microscope.

### Flow Cytometry {#S0003-S2008-S3002}

OCI-LY8 cells were seeded in culture flasks (5×10^5^ cells per flask) and divided into six groups as follows: 1) control group (2 mL RPMI1640 medium); 2) Fe~3~O~4~ MNPs group (1 mg Fe/mL in 2 mL RPMI1640 medium); 3) MTX group (1mg/mL MTX in 2 mL RPMI1640 medium); 4) Fe~3~O~4~\@MTX MNPs group (1 mg Fe/mL in 2 mL RPMI1640 medium); 5) Fe~3~O~4~ MNPs + hyperthermia group (1 mg Fe/mL in 2 mL RPMI1640 medium) and 6) Fe~3~O~4~\@MTX MNPs + hyperthermia group (1 mg Fe/mL in 2 mL RPMI1640 medium). Cells were incubated in a humidified incubator (37°C, 5% CO~2~) for 48 hrs. For combined hyperthermia groups, cells were placed at AMF (f = 230 kHz, I = 30 A) for 1 hr after 24 hrs. After that, cells were collected and cell apoptosis analysis was performed with FCM (BD Biosciences, USA).

### Quantitative Real-Time Polymerase Chain Reaction (qPCR) {#S0003-S2008-S3003}

Total RNA was extracted from six groups of cells (control group, Fe~3~O~4~ MNPs group, MTX group, Fe~3~O~4~\@MTX MNPs group, Fe~3~O~4~ MNPs + hyperthermia group，Fe~3~O~4~\@MTX MNPs + hyperthermia group, each group was treated as above) using RNApure Tissue&Cell Kit (Cwbiotech, China) and dissolved in DEPC-treated water. After reverse transcription, the qPCR was performed in a 10μL total volume (Vazyme Biotech Co., Ltd, China) comprising 5μL of 2× ChamQ SYBR qPCR Master Mix, 0.2μL of 50× ROX Reference Dye 1, 0.2μL of 5ʹprimer (10μM), 0.2 μL of 3ʹprimer (10μM), 2.4μL of ddH2O and 2 μL of cDNA on the StepOnePlus™ Real-Time PCR System (Applied Biosystems). The melting curve and threshold cycle data for each PCR product were determined and analyzed. The sequences of the specific primers used in the research were as follows (5ʹ-3ʹ): Caspase-3-forward: TGGAATGACATCTCGGTC

TG and reverse: GGCTCAGAAGCACACAAACA; Bax-forward: TTTGCTTCAGGGTTTCATCC and reverse: CAGTTGAAGTTGCCGTCAGA; Bcl-2-forward: GCACAAATACTCCGCAAGAGA and reverse: GAGAGAATGTTGGCGTCTTG; GAPDH-forward: GAAGGTGAAGGTCGGAGTC and reverse: GAAGATGGTGATGGGATTTC.

### Western Blot {#S0003-S2008-S3004}

OCI-LY8 cells under different treatments (control group, Fe~3~O~4~ MNPs group, MTX group, Fe~3~O~4~\@MTX MNPs group, Fe~3~O~4~ MNPs + hyperthermia group, Fe~3~O~4~\@MTX MNPs + hyperthermia group as above) were lysed, and the protein concentrations were assessed using BCA assay. Proteins were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred from gel to polyvinylidene difluoride membranes. The membranes were blocked with nonfat milk and after the overnight incubation at 4°C with primary antibodies goat anti-Rabbit IgG (KeyGEN BioTECH, diluted 1:5000), membranes were washed and incubated with secondary antibodies for 2 hrs in dark (Caspase-3 antibody, 1:1000; Bax antibody, 1:1000; Bcl-2 antibody, 1:1000; GAPDH, 1:1000); then, the bands were set into molecular imager and signals were detected.

In vivo Evaluation of the Efficacy of Fe~3~O~4~\@MTX MNPs on Intracranial Tumor BALB/c-Nude Mice Model {#S0003-S2009}
------------------------------------------------------------------------------------------------------

### Establishment of Intracranial Tumor Models {#S0003-S2009-S3001}

Cultured OCI-LY8 cells were washed three times with PBS, counted and kept on ice in DMEM until injection. After anesthetized with 1% pentobarbital, mice were placed in a stereotactic frame. All BALB/c-Nude mice were injected in the right cerebral hemisphere with 5 × 10^5^ OCI-LY8 cells (5 μL, 1 μL/min) at 2.0 mm lateral and coordinates 0.5 mm anterior from the bregma and at an intraparenchymal depth of 3 mm. After injection, the needle was left in place for 5 mins after injection. All animal experiments were done following institutional ethics guidelines.

### MRI {#S0003-S2009-S3002}

The life state of the mice was observed daily after the operation, and tumor growth was monitored continuously by MRI after one week. After 12 days, tumor-bearing mice with tumor diameter of 0.5 cm were selected for followed experiments. Successfully modeled BALB/c-Nude mice were divided into six groups (4 mice in each group, half male and half female) as follows: 1) NaCl group (0.02 mL); 2) Fe~3~O~4~ MNPs group (1 mg Fe/mL in 0.02 mL NaCl); 3) MTX group (1mg/mL MTX in 0.02 mL NaCl); 4) Fe~3~O~4~\@MTX MNPs group (1 mg Fe/mL in 0.02 mL NaCl); 5) Fe~3~O~4~ MNPs + hyperthermia group (1 mg Fe/mL in 0.02 mL NaCl) and 6) Fe~3~O~4~\@MTX MNPs + hyperthermia group (1 mg Fe/mL in 0.02 mL NaCl). The configured solution was injected through the tail vein, and then, a strong magnet was placed above the head of the mice in combined hyperthermia groups. For heating, the tumors were exposed to AMF (f = 230 kHz, I = 30 A) three times for 1 hr each and a time interval of 24 hrs.

After six weeks of treatment, tumor size and targeted aggregation of MNPs were detected by MRI. Tumor size was calculated by the formula: V = 1/2 × a × b^2^ (V: tumor volume; a: the longest diameter; b: the shortest diameter).

### H&E Stain {#S0003-S2009-S3003}

Brains were removed after perfusion, part of the tumor tissues in each group were fixed, embedded, sectioned and stained with hematoxylin & eosin (H&E) for histopathologic analysis.

### qPCR and Western Blot of Tumor Tissues {#S0003-S2009-S3004}

Part of tumor was then harvested and processed for determination of qPCR and Western blot. The tissues were fully ground in liquid nitrogen, and then the corresponding RNA and protein were extracted after adding the lysate separately. The following processes of quantifying and displaying the strips are as described above.

Statistical Analysis {#S0003-S2010}
--------------------

All statistical analyses were analyzed with SPSS version 19.0 software (SPSS Inc., Chicago, IL, USA); PS, Image J and Origin were commonly used mapping software. Values are shown as mean ± standard deviation (SD). A P-value of 0.05 was considered to be statistically significant.

Results {#S0004}
=======

Preparation and Characterization of Fe~3~O~4~ MNPs and Fe~3~O~4~@ MTX MNPs {#S0004-S2001}
--------------------------------------------------------------------------

We have developed a water-dispersible Pluronic F-127/OA-coated iron oxide magnetic nanoparticle formulation Fe~3~O~4~\@MTX MNPs. OA was chemisorbed on the surface of the Fe~3~O~4~ MNPs, MTX dispersed into the OA shell surrounding Fe~3~O~4~ MNPs, and the Pluronic F-127 that anchored at the OA-water interface conferred aqueous dispersity to the system ([Figure 1](#F0001){ref-type="fig"}). TEM showed Fe~3~O~4~ MNPs\' core to be approximately spherical in shape and the particles were uniform in size relatively, 16 nm in diameter ([Figure 2A](#F0002){ref-type="fig"}). Whole composite Fe~3~O~4~\@MTX MNPs size and size distribution were measured by NTA ([Figure 2B](#F0002){ref-type="fig"}). It showed that the formulation had an average hydrated diameter of 113 nm with a single peak and a narrow particle size distribution. Moreover, the magnetic properties of Fe~3~O~4~ MNPs and Fe~3~O~4~\@MTX MNPs were analyzed by VSM at room temperature. [Figure 2C](#F0002){ref-type="fig"} shows the hysteresis loops of the samples; there was no hysteresis in the magnetization, with both remanence and coercivity being zero, providing a good demonstration of the superparamagnetic properties. Zeta potential of Fe~3~O~4~ MNPs, OA-coated Fe~3~O~4~ MNPs and Pluronic F-127/OA-coated Fe~3~O~4~ MNPs were detected, respectively ([Figure 2D](#F0002){ref-type="fig"}). And, results show that modified MNPs are more stable than unmodified particles, especially Pluronic F-127/OA-coated Fe~3~O~4~ MNPs.Figure 1Pattern diagram of Fe~3~O~4~\@MTX MNPs synthesis process.**Notes：**OA was chemisorbed on the surface of the Fe~3~O~4~ MNPs, MTX dispersed into the OA shell surrounding Fe~3~O~4~ MNPs, and the Pluronic F-127 that anchored at the OA-water interface conferred aqueous dispersity to the system.**Abbreviations:** MNPs, magnetic nanoparticles; OA, oleic acid.Figure 2Characterization of Fe~3~O~4~\@MTX composite magnetic nano drug-loading system. (**A**) Transmission electron microscopy image of Fe~3~O~4~ MNPs carrier; (**B**) Hydrodynamic diameter and particle size distribution of Fe~3~O~4~\@MTX MNPs obtained by nanoparticle tracking analysis; (**C**) The hysteresis loops of Fe~3~O~4~ MNPs and Fe~3~O~4~\@MTX MNPs (insert); (**D**) Zeta potential of Fe~3~O~4~ MNPs, OA-Fe~3~O~4~ MNPs, Pluronic-F127/OA Fe~3~O~4~ MNPs and Fe~3~O~4~\@MTX MNPs.**Abbreviations:** MNPs, magnetic nanoparticles; OA, oleic acid.

Encapsulation and Cumulative Release of MTX {#S0004-S2002}
-------------------------------------------

Drug encapsulation efficiency and drug loading efficiency of nanoparticles are crucial properties for their clinical application. The amount of drug loaded was calculated by measuring the amount of MTX remaining in supernatants. [Figure 3](#F0003){ref-type="fig"} and [Table 1](#T0001){ref-type="table"} reveal the optimal drug encapsulation efficiency and drug loading efficiency. When drug loading efficiency was 15%, drug encapsulation efficiency reached the maximum value of 60.9%, which was selected for the next study.Table 1Encapsulation Efficiency and Drug Loading Efficiency of MTXDosing Ratio (%W/W)Loading Efficiency (%)Encapsulation Efficiency (%)52.15±0.143.9105.55±0.1758.7158.37±0.1560.9209.32±0.2151.2[^1] Figure 3Encapsulation efficiency and drug loading efficiency of MTX detected by UV-VIS-NIR spectrophotometer.**Note:** When drug loading efficiency was 15%, drug encapsulation efficiency reached the maximum value of 60.9%.

Release of MTX from the complex was also determined by UV-VIS-NIR spectrophotometer, and the cumulative release at various time points was summed ([Figure 4](#F0004){ref-type="fig"}). The drug release occurred in two phases: an initial burst release, with a signiﬁcant amount of drug released within 12 hrs; after 12 hrs, the MTX release proﬁles showed a sustained release pattern and cumulative amount reached 26.3% at 25°C, up to 33.3% at 42°C within 72 hrs.Figure 4Drug release curve of Fe~3~O~4~\@MTX MNPs at different temperatures.**Note:** The drug release occurred in two phases: an initial burst release within 12 hrs and a sustained release after that.**Abbreviation:** MNPs, magnetic nanoparticles.

Increasing Temperature Tests {#S0004-S2003}
----------------------------

The iron concentrations of the Fe~3~O~4~ MNPs were set 0.5, 1.0 and 1.5 mg Fe/mL, respectively. It demonstrated that the temperature of Fe~3~O~4~ MNPs in AMF could quickly rise to 35.5°C, 37.2°C and 39.9°C within 25 mins. After 30 mins, the temperature rose gently and almost remained at 38.5°C--44.1°C which was sufficient for heating efficacy ([Figure 5A](#F0005){ref-type="fig"}). Here, we chose 1.0mg Fe/mL as the subsequent therapeutic concentration and compared the heating capacity of Fe~3~O~4~\@MTX MNPs of the same iron concentration with ddH~2~O, as shown in [Figure 5B](#F0005){ref-type="fig"}.Figure 5Heating capacity of MNPs at alternating magnetic field (**A**) Heating curve of Fe~3~O~4~ MNPs (0.5, 1.0, 1.5mg Fe/mL); (**B**) Heating curve of Fe~3~O~4~\@MTX MNPs compared with Fe~3~O~4~ MNPs and ddH~2~O (1.0mg Fe/mL).**Abbreviation:** MNPs, magnetic nanoparticles.

Biocompatibility {#S0004-S2004}
----------------

### Cell Cytotoxicity {#S0004-S2004-S3001}

The morphological changes of 3T3 cells after treatment with different concentrations of Fe~3~O~4~ MNPs and Fe~3~O~4~\@MTX MNPs were observed by inverted microscopy. With the same Fe concentration, shapes and growth of the Fe~3~O~4~ MNPs-treated cells were basically similar to normal cells; they exhibited clear edges, and no cell fragments, while most of the Fe~3~O~4~\@MTX MNPs-treated cell became round and fell off ([Figure 6A](#F0006){ref-type="fig"}). The results of the CCK-8 assay were shown in [Figure 6B](#F0006){ref-type="fig"}. When at 500μg Fe/mL, the cell survival rate of Fe~3~O~4~-treated group was still 80%. This was similar with the outcomes from inverted microscopy and demonstrated that Fe~3~O~4~ MNPs had less cytotoxicity in vitro.Figure 6Biocompatibility of Fe~3~O~4~ MNPs carrier (**A**) Inverted microscopy images of 3T3 cells incubated with Fe~3~O~4~ MNPs and Fe~3~O~4~\@MTX MNPs; (**B**) CCK-8 assay of Fe~3~O~4~ MNPs and Fe~3~O~4~\@MTX MNPs.**Abbreviations:** MNPs, magnetic nanoparticles; CCK-8, cell counting kit-8.

### MN Results of Fe~3~O~4~ MNPs {#S0004-S2004-S3002}

In our study, the MN formation rates of 5.00, 3.75, 2.50 and 1.25 g/kg experimental groups, negative control group and positive control group were 2.56‰, 2.41‰, 2.29‰, 2.1‰, 2.09‰ and 26.65‰, respectively ([Figure 7](#F0007){ref-type="fig"}), showing a significant difference between the experimental groups and the positive control group (*P*\<0.05). But MN formation rates at different doses of experimental groups showed no statistical difference compared with the negative control group (*P*\>0.05). These results indicated that Fe~3~O~4~ MNPs as our carrier were not genotoxic.Figure 7Genotoxicity of Fe~3~O~4~ MNPs carrier.**Notes:** n = 10. ^a^P \> 0.05, MN formation rates of Fe~3~O~4~ MNPs groups compared with negative control; ^b^P \< 0.05, MN formation rates between Fe~3~O~4~ MNPs groups and positive control.**Abbreviations:** MN, micronucleus; PEC, polychromatic erythrocytes, MNPs, magnetic nanoparticles.

### Acute Toxicity in Mice Fe~3~O~4~\@MTX MNPs {#S0004-S2004-S3003}

Some behavioral changes such as crouching, apathy and slow response to external stimulus were observed among some animals immediately after Fe~3~O~4~\@MTX MNPs injection; most of them resumed normal activity rapidly. The deaths of mice in each group occurred during these 14 days after administration ([Table 2](#T0002){ref-type="table"}). SPSS were used to calculate the LD~50~ of Fe~3~O~4~\@MTX MNPs, which evaluated short-term toxicity after intraperitoneal administration. The LD~50~ of the complex nano drug-loading system to the mice was 8.579 g/kg, and its 95% confidence interval (CI) was 6.300--12.333 g/kg from the acute toxicological study.Table 2Acute Toxicity Test for Detecting LD~50~ of Fe~3~O~4~\@MTX MNPsGroupDosagenDeath Number11.7710022.5110033.5410245.0010357.0610369.98104714.09108819.891010[^2][^3]

In vitro Evaluation of the Efficacy of Fe~3~O~4~\@MTX MNPs on OCI-LY8 PCNSL Cells {#S0004-S2005}
---------------------------------------------------------------------------------

### Perls Stain {#S0004-S2005-S3001}

The stained OCI-LY18 cells were observed under an inverted microscope (10╳100). It was shown that iron reacted with potassium ferrocyanide to form iron ferrocyanide precipitated in the intracellular iron, which manifested that Fe~3~O~4~\@MTX complex MNPs could enter OCI-LY18 cells easily ([Figure 8](#F0008){ref-type="fig"}).Figure 8The labeling effect of Fe~3~O~4~\@MTX MNPs on OCI-LY18 cells by Perls.**Note:** Fe~3~O~4~\@MTX MNPs could get into OCI-LY18 cells, 10×100 magnification.**Abbreviation:** MNPs, magnetic nanoparticles.

### Apoptosis Assay {#S0004-S2005-S3002}

The rate of apoptotic OCI-LY18 cells after 48 hrs of treatment is shown in [Figure 9](#F0009){ref-type="fig"}. It showed that the main function of our therapy was to induce apoptosis of OCI-LY18 cells in vitro. The percentages of apoptotic cells in control group were 7.21±3.68%, while the percentages of apoptotic cells after treatment with Fe~3~O~4~ MNPs, Fe~3~O~4~ MNPs with hyperthermia, MTX, Fe~3~O~4~\@MTX MNPs and Fe~3~O~4~\@MTX MNPs with hyperthermia were 13.87±1.36%, 31.35±3.02%, 28.51±0.99%, 17.22±2.71% and 52.00±5.50%, respectively. The function of hyperthermia at temperatures over 42°C is to cause inhibition of cellular enzymes and cell damage most probably through the process of apoptosis.[@CIT0026] In our research, the magnetic nanoparticle hyperthermia groups could induce apoptosis even in the absence of MTX. Induction of apoptosis after treatment with Fe~3~O~4~ MNPs combined with hyperthermia was considerably greater than in the Fe~3~O~4~ MNPs group (*P*\<0.01) and control group (*P*\<0.01). At the same time, apoptosis rate in Fe~3~O~4~\@MTX MNPs combined with hyperthermia group was considerably greater than in the Fe~3~O~4~\@MTX MNPs group (*P*\<0.01) and MTX group (*P*\<0.01). These results suggested that when combined with hyperthermia, Fe~3~O~4~\@MTX MNPs were more effective in terms of inhibiting cell proliferation.Figure 9Apoptosis rate of OCI-LY18 cells determined by flowcytometry.**Notes:** Apoptosis rate: control group (7.21±3.68%), Fe~3~O~4~ MNPs group (13.87±1.36%), MTX group (31.35±3.02%), Fe~3~O~4~\@MTX MNPs group (28.51±0.99%), Fe~3~O~4~ MNPs with hyperthermia group (17.22±2.71%), Fe~3~O~4~\@MTX MNPs with hyperthermia group (52.00±5.50%). *P*\<0.01, Fe~3~O~4~+H vs Control and FE~3~O~4~ groups; *P*\<0.01, Fe~3~O~4~\@MTX+H vs MTX and Fe~3~O~4~\@MTX groups.**Abbreviation:** MNPs, magnetic nanoparticles.

### qPCR and Western Blot {#S0004-S2005-S3003}

Transcription and translation of apoptosis-related gene Caspase-3, Bax and Bcl-2 were detected by qPCR and Western blot after OCI-LY18 cells of each experimental group were treated in the incubator for 48 hrs. The transcription of Caspase-3 gene in the Fe~3~O~4~\@MTX MNPs group were enhanced by hyperthermia which were significantly higher than that of Fe~3~O~4~ MNPs hyperthermia group (*P*\<0.05), Fe~3~O~4~\@MTX MNPs non-hyperthermia group (*P*\<0.01) and MTX chemotherapy group (*P*\<0.01). At the same time, the transcription of Bax gene in the Fe~3~O~4~\@MTX MNPs group were enhanced by hyperthermia which were significantly higher than that of Fe~3~O~4~\@MTX MNPs non-hyperthermia group (*P*\<0.05) and MTX chemotherapy group (*P*\<0.01). The transcription of Bcl-2 gene in the Fe~3~O~4~\@MTX MNPs was inhibited by hyperthermia which were significantly lower than that of Fe~3~O~4~\@MTX MNPs non-hyperthermia group (*P*\<0.01) and MTX chemotherapy group (*P*\<0.01). In addition, the transcription apoptosis-inducing gene Caspase-3 and Bax in the Fe~3~O~4~ MNPs with hyperthermia group were higher than that of Fe~3~O~4~ MNPs non-hyperthermia group (Caspase-3 gene, *P*\<0.05; Bax gene, *P*=0.079), and apoptosis-inhibiting gene Bcl-2 in the Fe~3~O~4~ MNPs hyperthermia group were significantly lower than that of Fe~3~O~4~ MNPs non-hyperthermia group (*P*\<0.01), as [Figure 10A](#F0010){ref-type="fig"}. The protein expressions of Caspase-3, Bax and Bcl-2 in OCI-LY18 cells treated with different groups for 48 hrs were detected by Western blotting. [Figure 10B](#F0010){ref-type="fig"} shows that Fe~3~O~4~\@MTX MNPs with hyperthermia could significantly upregulate the expression levels of Caspase-3, Bax, and downregulate Bcl-2. These results are consistent with the findings at gene level.Figure 10qPCR and Western blot analyses of OCI-LY18 cells after different treatments. (**A**) Transcription of Caspase-3, Bax and Bcl-2 genes were detected by qPCR; (**B**) Expression of Caspase-3, Bax and Bcl-2 proteins were detected by Western blot.**Notes:** \* P\<0.05; \*\* P\<0.01.

In vivo Evaluation of the Efficacy of Fe~3~O~4~\@MTX MNPs on Intracranial Tumor BALB/c-Nude Mice Model {#S0004-S2006}
------------------------------------------------------------------------------------------------------

### MRI and H&E Stain {#S0004-S2006-S3001}

MRI was performed 12 days after tumor implantation, and the results showed that the modeling was successful, and the mice with tumor in diameter about 0.5 cm was selected for treatment. After administration, MRI showed a low-signal region where MNPs accumulated in tumor location after a strong magnet was placed on the right side of the mice brain ([Figure 11A](#F0011){ref-type="fig"}). As [Figure 11B](#F0011){ref-type="fig"} and C, the tumor volume of the Fe~3~O~4~+MTX+H group was significantly lower than that of the MTX group (*P*\<0.05). The tumor volume of the Fe~3~O~4~+H group was significantly lower than in the Fe~3~O~4~ group (*P*\<0.05). The result indicated that Fe~3~O~4~\@MTX MNPs with hyperthermia could significantly reduce tumor volume, and thus inhibit the tumor progression.Figure 11MRI detection of targeting and treatment effect. (**A**) Low signal region showed that MNPs could concentrated at tumor site after the application of a magnet; (**B**) MRI images after different treatment effects; (**C**) Volume of tumors in various treatment groups.**Notes:** Low signal region indicated by the arrow in [Figure 11A](#F0011){ref-type="fig"} shows MNPs could target tumor tissues under the guidance of external magnetic field; High signal regions indicated by the arrows in [Figure 11B](#F0011){ref-type="fig"} show tumors after various treatments; \* P\<0.05.**Abbreviation:** MNPs, magnetic nanoparticles.

Brain tissues of each group were taken and fixed by formalin immediately after perfusion, and the results were observed after H&E staining ([Figure 12](#F0012){ref-type="fig"}). The number of tumor cells in the combined thermochemotherapy Fe~3~O~4~\@MTX MNPs group was significantly reduced compared with the single chemotherapy group and replaced by cell interstitial, which was consistent with the imaging results.Figure 12Histopathologic changes in various treatment groups.**Notes:** Hematoxylin & eosin staining, 10×100 magnification. The arrows illustrate tumor cells disappear at these areas.

### qPCR and Western Blot of Tumor Tissues {#S0004-S2006-S3002}

The transcription of apoptosis-inducing genes Caspase-3 and Bax in Fe~3~O~4~\@MTX+H group were significantly higher than in MTX group, Fe~3~O~4~\@MTX group and Fe~3~O~4~+H group (*P*\<0.05). The transcription of Caspase-3 in Fe~3~O~4~+H group was also higher than in Fe~3~O~4~ group (*P*=0.399) and Bax transcription level of the Fe~3~O~4~+H group was also increased compared with the Fe~3~O~4~ group (*P*=0.506); the transcription of apoptosis-inhibiting gene Bcl-2 in Fe~3~O~4~\@MTX+H group was lower than in MTX group (*P*=0.059); Bcl-2 in Fe~3~O~4~+H group was also significantly lower than in Fe~3~O~4~ group (*P* \<0.05) ([Figure 13A](#F0013){ref-type="fig"}). The protein expressions of Caspase-3, Bax and Bcl-2 in tumor tissues were examined by Western blot as shown in [Figure 13B](#F0013){ref-type="fig"}. Semi-quantitative results were basically consistent with qPCR results ([Figure 13C](#F0013){ref-type="fig"}). Caspase-3 and Bax were upregulated in Fe~3~O~4~\@MTX+H group (*P*\<0.05), while Bcl-2 were downregulated both in Fe~3~O~4~\@MTX+H and Fe~3~O~4~+H groups (*P*\<0.05). The above findings in vivo were consistent with in vitro study, which indicated that Fe~3~O~4~\@MTX MNPs combined with hyperthermia could induce apoptosis of tumor cells better.Figure 13qPCR and Western blot analyses of tumor tissues after different treatments. (**A**) Transcription of Caspase-3, Bax and Bcl-2 genes were detected by qPCR; (**B**) Expression of Caspase-3, Bax and Bcl-2 proteins were detected by Western blot; (**C**) Semi-quantitative results of Caspase-3, Bax and Bcl-2 proteins.**Notes:** \* P\<0.05; \*\* P\<0.01.

Discussion {#S0005}
==========

Combination therapy is the most promising treatment method, aiming to improve efficacy and reduce the dosage of single drug. The application of traditional treatments for tumors has gradually shown many limitations. Magnetic fluid hyperthermia as a special physical way，which could increase the temperature above 42°C and targeted to various tumor cells and tissues, has gained more and more attention and recognition.[@CIT0018] Superparamagnetic iron oxide nanoparticles have been widely used in imaging, drug delivery and heating,[@CIT0027],[@CIT0028] and their combination with surgery, radiotherapy, chemotherapy and even ultrasound[@CIT0029] has shown excellent outcomes in both in vitro and in vivo experiments on liver,[@CIT0030],[@CIT0031] breast,[@CIT0032]--[@CIT0035] colon[@CIT0036]--[@CIT0039] and brain cancers.[@CIT0040]--[@CIT0043]

In our study, we have developed water-dispersible superparamagnetic MTX loaded Pluronic F-127/OA-coated Fe~3~O~4~ MNPs, which had an average hydrated diameter of 113 nm ([Figure 2B](#F0002){ref-type="fig"}). Superparamagnetic properties of MNPs in various research were proven well after coated with kinds of materials,[@CIT0025],[@CIT0044] [Figure 2C](#F0002){ref-type="fig"} shows that remanence and coercivity of our nano drug-loading system Fe~3~O~4~\@MTX MNPs were zero. After sequential modification successfully, zeta potential of Fe~3~O~4~ MNPs (−3.1mV) was decreased to −25.8mV of Pluronic F-127/OA-coated Fe~3~O~4~ MNPs in the neutral environment of pH 7.4 ([Figure 2D](#F0002){ref-type="fig"}). Compared with our previous research of Fe~3~O~4~\@Au-C225 MNPs (11.1±1.8 mV),[@CIT0045] the final Fe~3~O~4~\@MTX MNPs was negatively charged (−22.2mV), which may help to bind to positively charged cells. The maximum drug encapsulation efficiency was 60.9% when drug loading efficiency was 15% ([Figure 3](#F0003){ref-type="fig"} and [Table 1](#T0001){ref-type="table"}); thus, Fe~3~O~4~\@MTX MNPs we used for subsequent treatment reduced the dose of MTX by about 40%. Furthermore, the MTX release proﬁles showed a sustained release pattern and cumulative amount of MTX release was 26.3% at 25°C and reached 33.3% at 42°C in 72 hrs after initial 12 hrs which indicated that our formulation may extend the cycle time of MTX in body and improved treatment efficiency ([Figure 4](#F0004){ref-type="fig"}). Heating capacity of Fe~3~O~4~\@MTX MNPs was compared with Fe~3~O~4~ MNPs and ddH~2~O shown as in [Figure 5](#F0005){ref-type="fig"}. Biocompatibility of our Fe~3~O~4~ MNPs carrier was tested in 3T3 cells and KM mice and results showed less cell cytotoxicity and no genotoxic ([Figures 6](#F0006){ref-type="fig"} and [7](#F0007){ref-type="fig"}). The results of acute toxicity test showed that LD~50~ of Fe~3~O~4~\@MTX MNPs drug-loading system was 8.579 g/kg ([Table 2](#T0002){ref-type="table"}); moreover, the safety range (95% CI: 6.300--12.333 g/kg) was wider than Fe~3~O~4~\@Au composite MNPs (95% CI: 6.58--10.72 g/kg).[@CIT0025]

In vitro, the cell apoptosis was measured by flow cytometry ([Figure 9](#F0009){ref-type="fig"}), and then qPCR and Western blot were performed to evaluate the molecular mechanisms of inducing apoptosis in OCI-LY18 cells and mice tissues ([Figures 10](#F0010){ref-type="fig"} and [13](#F0013){ref-type="fig"}). Tamas Vancsik et al indicated that hyperthermia could significantly reduce anti-apoptotic XIAP, BCL-2 and BCL-XL and elevated pro-apoptotic BAX and PUMA, may further raise the sensitivity and/or reduce the therapeutic concentration and side effects of Dox.[@CIT0026] The results of Mantso et al showed that hyperthermia can exert therapeutic effectiveness against melanoma and colon carcinoma by inhibiting a number of critical cellular cascades including apoptosis, proliferation and DNA damage.[@CIT0046] The combined thermohyperthermia mediated by Fe~3~O~4~\@MTX MNPs in our study exhibited superior therapeutic efficacy on OCI-LY18 PNCSL cells by synergistic effects between chemotherapy and apoptosis, transcription and translation of apoptosis-inducing gene Caspase-3; Bax were significantly upregulated while apoptosis-inhibiting gene Bcl-2 were significantly inhibited in combined hyperthermia groups, indicating its excellent antitumor effect by inducing intrinsic apoptosis. After successful construction of mice intracranial tumor models, in vitro results indicated that hyperthermia can help inhibit tumor cells and thermochemotherapy of Fe~3~O~4~\@MTX+H group achieved significant therapeutic effects compared with other groups. Both MRI and pathology supported this conclusion ([Figures 11](#F0011){ref-type="fig"} and [12](#F0012){ref-type="fig"}). Furthermore, MRI in vivo show that the intensity and signal change rate of tumor tissues were decreased after tail vein injection of Fe~3~O~4~\@Au-C225 composite targeted MNPs indicated by Ge et al.[@CIT0047] Our findings are similar with Ali Shakeri-Zadeh et al[@CIT0048] which states that MNPs could be guided by an external magnetic field and immobilized in the tumor as observed by the dark regions. Recently, some study indicated folate-conjugated gold nanoparticles could increase the efficiency of cancer diagnosis and therapy, which inspires us to improve our modification on Fe~3~O~4~ nanoparticles to get better targeting.[@CIT0049]

Conclusion {#S0006}
==========

In summary, we have successfully constructed and characterized Fe~3~O~4~\@MTX nano drug-loading system which could combine efficiently magnetic targeting, magnetic hyperthermia and chemotherapy into a whole. In addition, the combined effect could significantly improve the treatment effect, while reducing the use of chemotherapy drugs to avoid side effects. Finally, we conducted a preliminary exploration of the feasibility and possible mechanisms of inducing tumor apoptosis. In addition, we have performed proteomics to detect new possible proteins and acetylation sites in the MTX single chemotherapy group and Fe~3~O~4~\@MTX+H thermochemotherapy group, and further optimize the hyperthermia conditions to explore whether the combined hyperthermia could stably inhibit the MTX key enzyme dihydrofolate reductase (DHRF) to solve the drug tolerance problems.
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[^1]: **Notes:** n = 3, mean ± standard deviation.

[^2]: **Notes:** LD~50~ of Fe~3~O~4~\@MTX MNPs was 8.579 g/kg (95% CI: 6.300--12.333 g/kg).

[^3]: **Abbreviations:** LD~50~, median lethal dose; CI, confidence interval; MNPs, magnetic nanoparticles.
